Navigation Links
Amgen's Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To $1.29
Date:7/27/2009

diac myosin activator being developed for the treatment of heart failure.

Emerging Pipeline: The Company provided an update on several of its clinical programs:

AMG 102: In Phase 2 studies, limited efficacy was seen in glioblastoma multiforme and renal cell carcinoma when AMG 102 was administered in monotherapy, but the effect size was not large enough to warrant moving forward with late-stage studies in these indications. Phase 2 combination studies with AMG 102 in the gastric, prostate, mCRC, and small cell lung cancer settings continue.

Dulanermin: The Company has received a preliminary report on the Phase 2 NSCLC study with dulanermin (rhApo2L/TRAIL), which is being developed in collaboration with Genentech. The Phase 2 program continues to progress and the Company will be reviewing the complete NSCLC data set with Genentech later this year.

AMG 222: The Company has received results from a Phase 2a study of AMG 222 in patients with type 2 diabetes. The results support continued Phase 2 development of AMG 222.

AMG 785: The Company announced that it is in the process of initiating Phase 2 studies of AMG 785 (Sclerostin) in fracture healing and postmenopausal osteoporosis

Non-GAAP Financial Measures

Management has presented its operating results in accordance with GAAP and on an "adjusted" (or non-GAAP basis) for the three and six months ended June 30, 2009 and 2008. In addition, management has presented its outstanding debt in accordance with GAAP and on an "adjusted" (or non-GAAP basis) on June 30, 2009. The Company believes that the presentation of non-GAAP financial measures provides useful supplementary information to and facilitates additional analysis by investors. The Company uses these non-GAAP financial measures in connection with its own budgeting and financial
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27

Related medicine news :

1. Burgeoning Population of Hepatitis C Virus Patients in Need of Second- and Third-Line Treatment Options
2. Medical Services International Maintains Pace in Second Quarter
3. CEOs Need an Advertising Check Up or Second Opinion
4. Trojan(R) Ranks U.S. Colleges and Universities in Second Annual Sexual Health Report Card
5. HealthMedia Revolution Explodes in Second Quarter
6. J.D. Power and Associates Reports: CIGNA HealthCare Recognized for Call Center Customer Satisfaction Excellence For a Second Consecutive Year
7. Acting Surgeon General Announces National Initiatives to Protect Children by Reducing Exposure to Secondhand Smoke
8. Roller Derby Author Cheats Death a Second Time
9. Launch of second European Cancer Research Funding survey
10. Secondhand smoke increases teen test failure
11. Elder Care Author Doctor Marion Launches Second National Tour to Raise Awareness About Aging & Elder Care Issues in America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... SAN DIEGO, Dec. 15 "The entire San ... mourns the passing of Sol Price on December 14, ... standards of integrity, loyalty and ethics in his business, ... and thoughtful humanitarian who truly understood the responsibility of ... and his legacy will live on through his countless ...
(Date:12/15/2009)... A study in the Dec. 15 issue of ... indicates that significant associations exist between parent-reported insomnia ... headaches in young school-aged children. , Results ... was 3.3 times more likely in children with ... children with headaches. Nineteen percent of children ...
(Date:12/14/2009)... Research Focuses on Unmarried Young Adults, Attitudes and Behavior ... WASHINGTON, Dec. 15 Nearly all unmarried young ... be planned (94% of men and 86% of women) ... in their lives right now (86% of men and ... The National Campaign to Prevent Teen and Unplanned Pregnancy. ...
(Date:12/14/2009)... particles carry oxygen, drugs, and more… , ... ... Santa Barbara, in collaboration with scientists at University of Michigan, ... key functions of natural red blood cells, including softness, flexibility, ... , ,The primary function of natural red blood cells is ...
(Date:12/14/2009)... Mich., Dec. 14 Pepsi Bottling ... Commonwealth of Kentucky are among the major employers ... fall to help their employees make better decisions ... gives employees a personalized summary of their families, ... that care. With this personalized information, employees can ...
Breaking Medicine News(10 mins):Health News:San Diego Hospice and The Institute for Palliative Medicine on the Passing of Sol Price 2Health News:Insomnia symptoms linked with medical complaints in young school-aged children 2Health News:Insomnia symptoms linked with medical complaints in young school-aged children 3Health News:Although Most Unmarried Young Adults Want to Avoid Pregnancy, Many Don't Use Contraception, Know Little About It, and Think It Doesn't Make Much Difference 2Health News:Although Most Unmarried Young Adults Want to Avoid Pregnancy, Many Don't Use Contraception, Know Little About It, and Think It Doesn't Make Much Difference 3Health News:Synthetic Red Blood Cells Developed 2Health News:Synthetic Red Blood Cells Developed 3Health News:Corporations, Universities and State Governments Deploy Thomson Reuters Solution to Improve Employees' Benefit Selection Process 2
... Unit at ... the German Cancer Research Center, CHICAGO, Nov. 26 ... the Radiology Society of North,America (RSNA) Annual Congress, being held ... 1,000th Convertible Ultrasound(TM) platform,to the German Cancer Research Center. The ...
... Joint collaboration will bring alternative herbicide tolerant systems and ... more choice for farmers ... Bayer CropScience AG, Mertec,LLC and M.S. Technologies LLC announced ... to jointly develop and commercialize,several innovative trait technology products ...
... SOUTH BEND, Ind., Nov. 26 , WHO: The Adams family ... About Your Drink Family Challenge among hundreds of families ... entered the photo contest by submitting a ... part of a nationwide education campaign, the nation,s milk ...
... Prostate cancer patients often receive treatment that is ... dysfunction, according to a new study. Dr. James ... and co-investigators found that patients with certain pretreatment ... can lead to worse outcomes. The study is ...
... Revolutionary New Artis zeego*, Which Employs Robotic ... ... Capabilities, CHICAGO, Nov. 25 ... of,interventional imaging systems that offer breakthrough versatility,enhanced image quality and ...
... WASHINGTON, Nov. 24 The busy holiday,shopping season is ... of food and products they buy -- many of ... Services Secretary Mike Leavitt will visit,Pike Place Market on ... protect consumers., Secretary Leavitt recently presented President Bush ...
Other Medicine News:Health News:ZONARE Surpasses 1000th Worldwide z.one Ultrasound System Shipment 2Health News:ZONARE Surpasses 1000th Worldwide z.one Ultrasound System Shipment 3Health News:Bayer CropScience, Mertec and M.S. Technologies to Co-Develop New Soybean Trait Products 2Health News:Bayer CropScience, Mertec and M.S. Technologies to Co-Develop New Soybean Trait Products 3Health News:South Bend Area Family Wins Nationwide got milk? Contest 2Health News:South Bend Area Family Wins Nationwide got milk? Contest 3Health News:Many prostate cancer patients receive improper or 'mismatched' therapies 2Health News:Siemens Introduces Its New Generation of Artis Interventional Imaging Systems 2Health News:Siemens Introduces Its New Generation of Artis Interventional Imaging Systems 3Health News:Siemens Introduces Its New Generation of Artis Interventional Imaging Systems 4Health News:Siemens Introduces Its New Generation of Artis Interventional Imaging Systems 5Health News:HHS Secretary to Visit Pike Place Market to Discuss Import Safety, Preview Trip to China 2
(Date:12/15/2009)... Today, Hill-Rom Holdings, Inc. (NYSE: ... on significant strategic and financial initiatives at its ... Conference is hosted by Peter H. Soderberg, president ... on the following topics: ,, Status of ... development and financial updates Smart technologies that ...
(Date:12/15/2009)... Rib-X Pharmaceuticals, Inc., a company focused ... drugs for the treatment of serious multi-drug-resistant infections ... research agreement with Massachusetts General Hospital (MGH). ... collaboration, Dr. David Hooper of MGH will evaluate ... model to determine resistance development and to validate ...
(Date:12/15/2009)... SAN DIEGO, INDIANAPOLIS, and CAMBRIDGE, Mass., Dec. 15 ... AMLN ), Eli Lilly and Company (NYSE: ... ALKS ) today announced positive results from ... investigational diabetes therapy, to BYETTA® (exenatide) injection taken ... After 24 weeks of treatment, patients taking exenatide ...
Breaking Medicine Technology:Hill-Rom Investor Conference Features Business Strategy Updates and New Technologies 2Hill-Rom Investor Conference Features Business Strategy Updates and New Technologies 3Hill-Rom Investor Conference Features Business Strategy Updates and New Technologies 4Hill-Rom Investor Conference Features Business Strategy Updates and New Technologies 5Hill-Rom Investor Conference Features Business Strategy Updates and New Technologies 6Hill-Rom Investor Conference Features Business Strategy Updates and New Technologies 7Rib-X Pharmaceuticals Enters into Collaborative Agreement on Delafloxacin with Massachusetts General Hospital 2Rib-X Pharmaceuticals Enters into Collaborative Agreement on Delafloxacin with Massachusetts General Hospital 3Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 2Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 3Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 4Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 5Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 6Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 7First Defense Nasal Screen Comp Releases New Protection Product Just in Time for Pandemic Flu Season 55643 1First Defense Nasal Screen Comp Releases New Protection Product Just in Time for Pandemic Flu Season 55643 2First Defense Nasal Screen Comp Releases New Protection Product Just in Time for Pandemic Flu Season 55643 3First Defense Nasal Screen Comp Releases New Protection Product Just in Time for Pandemic Flu Season 55643 4Waismann Method Offers Safe Treatment for Dependency to Benzodiazepines 55641 1Waismann Method Offers Safe Treatment for Dependency to Benzodiazepines 55641 2Waismann Method Offers Safe Treatment for Dependency to Benzodiazepines 55641 3Watson Pharmaceuticals Receives FDA Approval for Generic PLAN B 28R 29 for Over the Counter Use 55640 1Watson Pharmaceuticals Receives FDA Approval for Generic PLAN B 28R 29 for Over the Counter Use 55640 2
... U.S.-based subsidiary of,Pharmexa A/S, presents selected data ... Influenza Conference entitled, "Options for,the Control of ... The,data show that a "universal" vaccine designed ... mice against,lethal experimental influenza virus challenge. , ...
... SAN FRANCISCO & NEW DELHI, India--(BUSINESS WIRE)--Jun 21, ... non-profit,pharmaceutical company, today announced that Phase 3 research,related ... (Paromomycin), was published in the current issue of ... trial shows,that the medicine paromomycin is safe, effective, ...
Other Medicine Technology:Pharmexa A/S (DK) - Pharmexa presents data from influenza program 2Research on New Treatment for Neglected Disease Published in The,New England Journal of Medicine 2Research on New Treatment for Neglected Disease Published in The,New England Journal of Medicine 3Research on New Treatment for Neglected Disease Published in The,New England Journal of Medicine 4
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: